Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
The mesoderm/mesenchyme homeobox gene (Meox) belongs to the Homeobox gene (Hox). Homeobox genes are expressed in almost all eukaryotes, with 11 gene types in animals, more than 100 gene families, and 14 gene types in plants. The Meox gene is a member of a subfamily of homeobox genes that are expressed in mesoderm and mesenchyme, and the encoded protein may regulate somatic development. The Meox family has two members, including Meox1 and Meox2, and 98% of the amino acid sequences are identical. The difference between the two sequences is mainly outside the highly conserved region.
In the primitive stage of embryonic development, Meox1 forms mesodermal expression in the original head and heart in the future, rather than in the ectoderm and endoderm of neural tissue. Thus, mesodermal/mesomeric homeobox genes form mesoderm and neuroectoderm before or at the initial stage, and Meox1 expression may have revealed a broad "post-path" domain of embryonic mesoderm. In the newly formed somites, the expression of Meox1 is expressed throughout the somites of the skeletal and dermatomes, and when the body is segmented, Meox1 is restricted to the expression of the dermatomes. Skeletal muscle growth is driven by stem cells, which have extensive clonal drift. The homeobox gene meox1 controls clonal drift during muscle growth.
Figure 1. The homeobox gene meox1 controls clonal drift during muscle growth. (Nguyen, P. D., et al. 2017)
Meox1 Regulation of Cardiovascular System
To investigate the role of Meox1 in the differentiation of smooth muscle cells, it was found that transforming growth factor-β induces Meox1 expression in the initial stage of smooth muscle cell differentiation of pluripotent mesenchymal C3H10T1 /2 cells. Moreover, specific inhibitors block both PI3K and Smad3 signaling pathways, resulting in decreased expression of Meox1 and smooth muscle cell markers. Importantly, knockdown of Meox1 by specific shRNA inhibited TGF-β-induced expression of early markers of smooth muscle cells, including SM22α and calponin. On the other hand, Meox1 overexpression increases smooth muscle cell marker expression. These results indicate that Meox1 is a novel regulator of TGF-β-induced smooth muscle cell differentiation.
After the Meox1 gene was transfected into chick embryos at an early developmental stage for several hours, it was found to affect the division of cardiomyocytes in the early cardiac cyclization phase and inhibit cardiomyocyte proliferation. This study suggests that Meox1 may negatively regulate the proliferation of cardiomyocytes, and premature expression of homeobox genes in embryonic heart development may lead to normal morphogenesis in the heart. Overexpression of Meox1 in the heart of transgenic mice leads to dilated cardiomyopathy, suggesting that Meox1 may be one of the modified genes that enhance the pathogenesis of cardiomyopathy.
Regulation of Cardiac Fibroblasts by Meox1
The study found that Meox1 does not affect phenotypic changes in fibroblasts and myofibroblasts. The study found that Meox1 is expressed in the interstitial fibrosis region of heart failure, and Meox1 is expressed in vitro and in vivo with limited expression of cardiac fibroblasts. Paracrine signals from cardiomyocytes can increase Meox1-positive fibroblasts, and Meox1 knockdown completely inhibits reactive proliferation of cardiac fibroblasts. Gene expression indicated that knockdown of Meox1 resulted in down-regulation of mitosis-related gene expression. In fact, Meox1 knockdown reduces mitotic cells, which in turn increases the proportion of DNA-synthesized cells, thereby inhibiting the transition of mitosis. Synchronous cell cycle analysis and promoter analysis using live cell imaging indicated that Meox1 oscillated throughout the cell cycle and specifically appeared in the G2/M phase. Meox1, which is heterologously expressed in interstitial fibrosis, is derived from ventricular heart tissue in patients with end-stage heart failure. It is noteworthy that Meox1 expression is significantly associated with fibrosis-associated genes in diseased ventricular tissues, indicating pathological relevance in the clinical setting.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.